Colgate-Palmolive (CL) Earnings Date & Reports

Key Takeaways

• Earnings release date: Colgate-Palmolive is scheduled to report second quarter 2026 results on Friday, July 31, 2026, before the market opens, with a conference call at 8:30 a.m. ET.
• Consensus estimates: Wall Street analysts project earnings per share (EPS) of approximately $0.95 to $0.96 and revenue of roughly $5.31 billion to $5.36 billion for the second quarter.
• Year-ago comparison: In Q2 2025, Colgate-Palmolive reported EPS of $0.92 on revenue of $5.11 billion, meaning current estimates imply modest year-over-year growth on both the top and bottom line.
• Margin scrutiny: Gross margin trajectory will be a focal point after management revised full-year 2026 gross margin guidance downward in Q1, citing material cost inflation and tariff-related headwinds.
• Recent momentum: The company enters Q2 with positive momentum after Q1 2026 Base Business EPS of $0.97 beat consensus by roughly 2%, supported by organic sales growth of 2.9% and broad-based category performance.

Earnings Context and Why It Matters

Colgate-Palmolive's Q2 2026 report lands at a pivotal moment for the consumer staples giant. With a presence in over 200 countries spanning Oral Care, Personal Care, Home Care, and Pet Nutrition under the Hill's brand, the company is a bellwether for global consumer demand. The report will be closely parsed for evidence that pricing power can offset intensifying cost pressures — particularly raw material inflation linked to elevated oil prices and logistics costs, as well as the impact of tariffs in North America. Colgate-Palmolive's global toothpaste market share of 41.1% and manual toothbrush share of 32.6% underscore its category dominance, but investors are increasingly focused on whether its expanded Strategic Growth and Productivity Program (SGPP) can protect margins without sacrificing volume growth.

Earnings Expectations

Analyst consensus, as tracked by Yahoo Finance and TipRanks, places Q2 2026 EPS at approximately $0.95 to $0.96, with revenue estimates clustering between $5.31 billion and $5.36 billion. This would represent a roughly 3% to 4% increase in EPS and a comparable rise in revenue versus the year-ago quarter, when the company posted EPS of $0.92 on $5.11 billion in sales.

Organic sales growth — which excludes the effects of foreign exchange, acquisitions, and divestitures — is expected to remain in positive territory, though the exit from the private label pet food business will create a modest headwind of approximately 20 to 30 basis points on the company-level organic growth rate. Q1 2026 organic sales rose 2.9%, and the company's full-year guidance calls for organic sales growth of 1% to 4%.

Investors will watch closely for any signal that the company's Base Business gross profit margin is stabilizing after declining 20 basis points to 60.6% in Q1. Management has already flagged that it expects full-year gross margin to be down on a Base Business basis, reversing earlier expectations for expansion — a concession to roughly $300 million in incremental raw material and logistics cost pressure modeled into the outlook, with oil assumed to average approximately $110 per barrel for the remainder of the year.

Historically, Colgate-Palmolive has a strong track record of meeting or exceeding consensus: the company has beaten EPS estimates in at least four consecutive quarters through Q1 2026, typically by 2% to 6%. The post-earnings stock reaction has generally been positive on beats, though sensitivity to margin commentary has increased.

AI Screener

As investors prepare for Colgate-Palmolive's Q2 earnings, tools like Tickeron's AI Screener can help filter the broader consumer staples and household products landscape for stocks exhibiting similar technical and fundamental characteristics. The AI Screener is an AI-powered stock and ETF discovery tool that enables traders and investors to scan thousands of securities using customizable filters such as industry classification, market capitalization, technical indicators, price patterns, and performance metrics. By surfacing trade ideas, trending stocks, and potential breakout candidates more efficiently than manual screening, it allows users to identify opportunities aligned with specific strategies. For those monitoring how the household products sector behaves around earnings season, the AI Screener offers a data-driven way to stay ahead of market movements.

Market Reaction and Investor Sentiment

Sentiment heading into the Q2 2026 report appears cautiously optimistic but tempered by macro uncertainty. Colgate-Palmolive shares traded around the $93 level in mid-June 2026, reflecting a price-to-earnings (P/E) ratio above 37, a premium that underscores investor confidence in the company's defensive characteristics and consistent execution. However, the stock's elevated multiple leaves limited room for disappointment, particularly on the critical gross margin line. The Q1 report triggered a premarket gain of roughly 2.4% after the company beat on both EPS and revenue, suggesting that the market continues to reward execution even in a challenging cost backdrop. Key risk factors for Q2 include larger-than-expected tariff impacts in North America, further commodity cost escalation, and any sign that consumer trade-down behavior is eroding volume in premium categories.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 print, several dynamics will shape Colgate-Palmolive's trajectory through the remainder of 2026. The company's full-year guidance, reaffirmed during Q1, calls for net sales growth of 2% to 6% (including a low-single-digit foreign exchange tailwind), organic sales growth of 1% to 4%, and Base Business EPS growth in the low-to-mid-single-digit range.

The expanded SGPP — with cumulative pretax charges now estimated at $350 million to $550 million and annual savings projected at $200 million to $300 million once fully implemented by the end of 2028 — represents a meaningful lever for margin recovery. However, the bulk of savings is not expected to materialize until 2027 and 2028, meaning near-term margin protection will depend more heavily on pricing actions and revenue growth management.

On the revenue side, Hill's Pet Nutrition remains a key growth engine and a point of differentiation versus pure-play household products peers. The strategic exit from private label pet food, while a near-term headwind, is designed to sharpen focus on higher-margin, science-led offerings under the Hill's Prescription Diet and Hill's Science Diet banners. Investors should also monitor geographic performance, particularly whether the strong momentum in Latin America and Asia-Pacific can continue to offset more sluggish conditions in North America. Advertising investment is expected to increase both in dollar terms and as a percentage of sales, signaling management's commitment to brand-building even amid cost pressures — a strategy that, if executed well, supports long-term market share resilience.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations